SEC 13F Intelligence

Clal Insurance Enterprises Holdings Ltd / TEVA

Clal Insurance Enterprises Holdings Ltd’s Teva Pharmaceutical Inds Ltd Position

Does Clal Insurance Enterprises Holdings Ltd own Teva Pharmaceutical Inds Ltd (TEVA)? Yes38.45M shares worth $1.1B (+6.91% of its 13F portfolio) as of Q1 2026, up from 37.40M shares the prior filed quarter.

Position Value
$1.1B
Q1 2026
Shares
38.45M
% of Portfolio
+6.91%
Quarters Held
30
currently held

Position History TEVA

Reported value by quarter
Q4 ’18: $58MQ4 ’18Q1 ’19: $48MQ2 ’19: $24MQ3 ’19: $18MQ4 ’19: $4.9BQ4 ’19Q1 ’20: $13MQ2 ’20: $202MQ3 ’20: $125MQ4 ’20: $131MQ4 ’20Q1 ’21: $166MQ2 ’21: $157MQ3 ’21: $172MQ4 ’21: $138MQ4 ’21Q1 ’22: $168MQ2 ’22: $138MQ3 ’22: $155MQ4 ’22: $169MQ4 ’22Q1 ’23: $161MQ2 ’23: $238MQ3 ’23: $312MQ4 ’23: $343MQ4 ’23Q1 ’24: $406MQ2 ’24: $526MQ3 ’24: $621MQ4 ’24: $860MQ4 ’24Q1 ’25: $578MQ2 ’25: $543MQ3 ’25: $633MQ4 ’25: $1.2BQ4 ’25Q1 ’26: $1.1Bfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202638.45M$1.1B+6.91%
Q4 202537.40M$1.2B+7.56%
Q3 202531.49M$633M+4.83%
Q2 202532.36M$543M+5.34%
Q1 202537.79M$578M+5.98%
Q4 202438.96M$860M+7.75%
Q3 202434.54M$621M+5.50%
Q2 202432.34M$526M+5.50%
Q1 202428.79M$406M+4.57%
Q4 202332.80M$343M+4.49%
Q3 202330.61M$312M+4.35%
Q2 202331.61M$238M+2.85%
Q1 202318.84M$161M+2.42%
Q4 202218.43M$169M+2.53%
Q3 202219.41M$155M+2.13%
Q2 202218.96M$138M+1.84%
Q1 202217.54M$168M+1.77%
Q4 202117.54M$138M+1.50%
Q3 202117.66M$172M+1.96%
Q2 202115.83M$157M+1.79%
Q1 202114.41M$166M+1.92%
Q4 202014.58M$131M+1.79%
Q3 202013.91M$125M+2.11%
Q2 202016.42M$202M+4.01%
Q1 2020119.6K$13M+13.06%
Q4 201948.3K$4.9B+5.29%
Q3 20192.60M$18M+0.44%
Q2 20192.60M$24M+0.55%
Q1 20193.09M$48M+1.19%
Q4 20183.78M$58M+1.52%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Clal Insurance Enterprises Holdings Ltd’s full portfolio or all institutional holders of TEVA.